Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

Autor: Zhou, Caicun, Huang, Dingzhi, Fan, Yun, Yu, Xinmin, Liu, Yunpeng, Shu, Yongqian, Ma, Zhiyong, Wang, Ziping, Cheng, Ying, Wang, Jie, Hu, Sheng, Liu, Zhihua, Poddubskaya, Elena, Disel, Umut, Akopov, Andrey, Dvorkin, Mikhail, Zheng, Wenjuan, Ma, Yiyuan, Wang, Yan, Li, Songzi, Yu, Cunjing, Rivalland, Gareth
Zdroj: In Journal of Thoracic Oncology January 2023 18(1):93-105
Databáze: ScienceDirect